Loading...
  • viruses
  • Specimens were tested at U.S. Flu VE Network laboratories using CDC's real-time reverse transcription-polymerase chain reaction (rRT-PCR) protocol for detection and identification of influenza viruses using dual-labeled probe chemistry. (cdc.gov)
  • illness
  • As of January 11, 2013, 24 states and New York City were reporting high levels of influenza-like illness, 16 states were reporting moderate levels, five states were reporting low levels, and one state was reporting minimal levels ( 3 ). (cdc.gov)
  • participants
  • Participants with at least one vaccine-related adverse event (AE) from the following four categories: solicited AEs, unsolicited AEs, serious AEs, and abnormal safety labs for severity grade 2 or higher, grade 3 only, and grade 4 or 5. (clinicaltrials.gov)
  • Participants in each vaccine group experiencing an individual adverse event (AE) by severity grade, relatedness to vaccine, for solicited AEs, unsolicited AEs, serious AEs and abnormal safety labs. (clinicaltrials.gov)
  • Participants in each vaccine group experiencing at least one abnormal symptom with any severity grade, grade 2 or higher, grade 3 or higher, and grades 4 and 5, by relatedness to vaccine, for solicited adverse events (AE), serious AEs and safety labs. (clinicaltrials.gov)
  • Feasibility
  • In the end, The report introduced Influenza Vaccine (Split Virion),Inactivated new project SWOT analysis Investment feasibility analysis investment return analysis and also give related research conclusions and development trend analysis on Global and China Influenza Vaccine (Split Virion),Inactivated industry. (pitchengine.com)